Enrolment (Day -28 to 0) | Follow-up(± 3 days) a | |||||||
---|---|---|---|---|---|---|---|---|
Visit period | Screening stage c | Visit 0 | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Additional visit b |
Visit time | Day -28 to 0 | day 0 | week 4 | Week 12 | Week 24 | Week 36 | Week 52 | – |
Basic condition | ||||||||
Signing informed consent | ● | |||||||
Demographic information d | ● | |||||||
General clinical information e | ● | |||||||
Efficacy assessments | ||||||||
SGRQ scale | ● | ● | ● | ● | ● | ● | ● | |
CAT scale | ● | ● | ● | ● | ● | ● | ● | |
Symptom scale | ● | ● | ● | ● | ● | ● | ● | ● |
Number of exacerbations and duration | ● | ● | ● | ● | ● | ● | ||
Number of hospitalizations and reasons | ● | ● | ● | ● | ● | ● | ||
Constitution of TCMf | ● | ● | ● | |||||
Safety assessments | ||||||||
Vital sign | ● | ● | ● | ● | ● | ● | ● | ● |
Physical examination | ● | ● | ● | ● | ● | ● | ● | |
HCG | ● | |||||||
Glycosylated Hemoglobin | ● | |||||||
Lung function | ● | |||||||
Blood routine | ● | ● | ● | |||||
NGHX | ● | ● | ● | |||||
Serum biochemicals | ● | ● | ● | |||||
Adverse events recorded | ● | ● | ● | ● | ● | ● | ● | |
Exploratory assessments g | ||||||||
Microecology of the respiratory tract | ● | ● | ● | ● | ● | ● | ● | |
Herpesvirus infection | ● | ● | ● | ● | ● | ● | ● | |
Classification and counting of lymphocytes | ● | ● | ● | ● | ● | ● | ● | |
Inflammatory cytokines | ● | ● | ● | ● | ● | ● | ● | |
Immunoglobulin | ● | ● | ● | ● | ● | ● | ● | |
Others | ||||||||
Starting time of treatment | ● | |||||||
Combination therapy | ● | ● | ● | ● | ● | ● | ● | |
Issue medications and diary cards | ● | ● | ● | ● | ● | |||
Recycle medications and diary cards | ● | ● | ● | ● | ● | |||
eCRF | ● | ● | ● | ● | ● | ● | ● | ● |